CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 180 filers reported holding CHEMOCENTRYX INC in Q1 2022. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $404,000 | -77.6% | 7,822 | -89.3% | 0.00% | -100.0% |
| Q2 2022 | $1,806,000 | -83.7% | 72,896 | -83.5% | 0.00% | -66.7% |
| Q1 2022 | $11,077,000 | -55.6% | 441,831 | -35.6% | 0.00% | -62.5% |
| Q4 2021 | $24,968,000 | +14.9% | 685,746 | -46.1% | 0.01% | +14.3% |
| Q3 2021 | $21,737,000 | +40.1% | 1,271,217 | +9.8% | 0.01% | +16.7% |
| Q2 2021 | $15,510,000 | +538.8% | 1,158,279 | +2344.5% | 0.01% | +500.0% |
| Q1 2021 | $2,428,000 | -42.8% | 47,383 | -30.9% | 0.00% | -50.0% |
| Q4 2020 | $4,243,000 | -73.4% | 68,536 | -76.4% | 0.00% | -77.8% |
| Q3 2020 | $15,933,000 | +259.7% | 290,763 | +277.8% | 0.01% | +200.0% |
| Q2 2020 | $4,429,000 | +245.2% | 76,964 | +141.1% | 0.00% | – |
| Q1 2020 | $1,283,000 | +215.2% | 31,927 | +210.0% | 0.00% | -100.0% |
| Q4 2019 | $407,000 | +107.7% | 10,300 | -28.6% | 0.00% | 0.0% |
| Q1 2018 | $196,000 | +172.2% | 14,429 | -10.0% | 0.00% | – |
| Q2 2016 | $72,000 | -79.9% | 16,035 | -70.3% | 0.00% | -100.0% |
| Q1 2014 | $358,000 | – | 53,968 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |